A study comparing the amount of metformin and after taking a combination tablet vs. separate tablets

Study identifier:D1691C00002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A two part, open label, randomized, phase I bioequivalence study comparing the fixed dose combination dapagliflozin/metformin IR tablet (2.5 mg/850 mg or 5 mg/1000 mg) vs. the free combination of dapagliflozin and metformin IR tablets, in healthy volunteers, in the fed state

Medical condition

Healthy Volunteers

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Dapagliflozin/Metformin, Dapagliflozin, Metformin

Sex

All

Actual Enrollment

120

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Jan 2010
Primary Completion Date: 01 Apr 2010
Study Completion Date: 01 Apr 2010

Study design

Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Oct 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Bristol-Myers Squibb

Inclusion and exclusion criteria